Previous 10 | Next 10 |
home / stock / kne:cc / kne:cc news
WINNIPEG, Manitoba, March 19, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove...
WINNIPEG, Manitoba, March 08, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that at the Bioscience Association of Manitoba (“BAM”) annual awards dinner held on March ...
WINNIPEG, Manitoba, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that at the special meeting of the shareholders of the Company held on February 20, 2024, Dr. Robert Huiz...
WINNIPEG, Manitoba, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that it has filed a patent on its revyve™ Antimicrobial Wound Gel Spray, a follow-on product to it...
WINNIPEG, Manitoba, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) today announces that the Company will be presenting its revyve™ Antimicrobial Wound Gel at the Boswick Burn ...
WINNIPEG, Manitoba, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on February 20, 2024, the Company will hold a special meeting of its shareholders (the “M...
WINNIPEG, Manitoba, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) today announces a correction to its press release dated December 28, 2023. The maturity date of the Company’s ...
WINNIPEG, Manitoba, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on December 19, 2023, it signed a non-binding offer for the sale of its interest in STEM Animal ...
WINNIPEG, Manitoba, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its third quarter 2023 financial results. Third Quarter Financial Highlights: Revenue from product and ser...
MacDonald Mines Exploration Ltd. (BMK:CA) is expected to report for quarter end 2023-09-30 ARHT Media Inc. (ART:CA) is expected to report for Q3 2023 Arianne Phosphate Inc. (DAN:CA) is expected to report for quarter end 2023-09-30 EQB Inc. (EQB:CA) is expected to report $2.85 for Q3 2...
News, Short Squeeze, Breakout and More Instantly...
WINNIPEG, Manitoba, July 17, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has received ISO 13485:2016 Medical Device Single Audit Program (“MDSAP”) Quality Certification as a designer, de...
WINNIPEG, Manitoba, July 11, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has signed a worldwide license agreement with Arizona-based Omni Bioceutical Innovations Inc. (“Omni”) for its c...
WINNIPEG, Manitoba, June 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has made its first commercial-scale sale of revyve™ Antimicrobial Wound Gel product (“revyve™”...